Mission Therapeutics Ltd.

Founded in 2011 by co-founders Niall Martin, Steve Jackson, and Xavier Jacq and based in Cambridge, UK, Mission Therapeutics Ltd. develops deubiquitylating enzyme drugs for the treatment of life-threatening diseases like neurodegenerative disease, kidney disease, fibrosis, and rare mitochondrial diseases. In March 2024, Mission Therapeutics Ltd. raised GBP 25.

2 million in Series D funding co-led by investors Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group, and Rosetta Capital. As of July 2024, the company is led by CEO Anker Lundemose.   Mission Therapeutics' product portfolio includes small-molecule inhibitors of specific DUBs. The company has developed a comprehensive library of more than 17,000 DUB-specific compounds, from which several lead candidates have emerged.

Among these, MTX652 and MTX325, both targeting the DUB USP30, MTX652 has advanced into clinical trials, while MTX325 is in pre-clinical development. These specific mitochondrial-associated DUBs with inhibitors are designed to treat a range of diseases, including heart failure, neurodegenerative diseases, including parkinson’s disease, duchenne muscular dystrophy (DMD), renal diseases such as acute kidney injury (AKI) and chronic kidney disease (CKD), as well as other indications such as idiopathic pulmonary fibrosis (IPF), and rare genetic mitochondrial diseases.   The company will use the March 2024 funding to advance the clinical development of its drug candidates.